Compare LGCB & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGCB | CING |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 26.4M |
| IPO Year | 2023 | 2021 |
| Metric | LGCB | CING |
|---|---|---|
| Price | $2.00 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 58.9K | ★ 125.5K |
| Earning Date | 07-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,993,265.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $1.22 | $3.20 |
| 52 Week High | $6.83 | $6.01 |
| Indicator | LGCB | CING |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 52.86 |
| Support Level | $1.76 | $3.82 |
| Resistance Level | $2.09 | $4.02 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 45.54 | 35.19 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.